Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 23, Art. 3 (pp. 34-56)    |    2022       

»

Present issues of treatment of poisoning with synthetic and natural cannabinoids

State scientific-research test Institute of military medicine of Defense Ministry of the Russian Federation
North-Western State Medical University named after I. I. Mechnikov

Brief summary

To date, despite the decrease in statistical data on the use of cannabinoids, the range of their structural analogues, having the same type action, has significantly expanded. The use of synthetic and natural cannabinoids is associated with the occurrence of life-threatening conditions and the induction of mental and somatic disorders. The increase in the number of synthetic cannabinoids with a polyreceptor mechanism of action caused an increase in demand in healthcare for research and development of etiotropic and pathogenetic therapy of poisoning with such compounds. The review considers options for treatment of cannabinoids intoxication. Neutral antagonists of the first type cannabinoid receptors (CB1) can be considered as means of etiotropic therapy (surinabant and drinabant) and among the pathogenetic therapy agents are cell signaling modulators (pregnenalon) and receptors forming heterodimers with CB1. Suggested scheme can be supplemented with drugs with cytoprotective properties


Key words

spices, cannabinoids, CB1 signaling, heterodimer, antidote, treatment, vaniloid receptor TRPV1, GPR55, endocannabinoid enhancers

Reference list

1. R. C. Agís-Balboa, G. Pinna, A. Zhubi, E. Maloku, et al., Proceedings of the National Academy of Sciences of the United States of America, 103(39), 14602-7 (2006); doi: 10.1073/pnas.0606544103.


2. G. Aksel, Ö. Güneysel, T. Taşyürek, E. Kozan, et al., Case reports in emergency medicine, 2015, 180921 (2015); doi: 10.1155/2015/180921.


3. A. Alipour, P. B. Patel, Z. Shabbir, and S. Gabrielson, The mental health clinician, 9(2), 93-99 (2019); doi: 10.9740/mhc.2019.03.093.


4. H. K. Andersen, G. G. Piroli, and K. B. Walsh, Journal of pharmacological and toxicological methods, 94(Pt 1), 44-49 (2018); doi: 10.1016/j.vascn.2018.05.001.


5. W. T. Booth, N. B. Walker, W. T. Lowther, and A. C. Howlett, Molecules (Basel, Switzerland), 24(20) (2019); doi: 10.3390/molecules24203672.


6. B. Bosier, P. J. Doyen, A. Brolet, G. G. Muccioli, et al., British journal of pharmacology, 172(22), 5333-46 (2015); doi: 10.1111/bph.13324.


7. A. J. Brown, British journal of pharmacology, 152(5), 567-75 (2007); doi: 10.1038/sj.bjp.0707481.


8. A. Busquets-Garcia, E. Soria-Gómez, B. Redon, Y. Mackenbach, et al., Molecular psychiatry, 22(11), 1594-1603 (2017); doi: 10.1038/mp.2017.4.


9. L. Callén, E. Moreno, P. Barroso-Chinea, D. Moreno-Delgado, et al., The Journal of biological chemistry, 287(25), 20851-65 (2012); doi: 10.1074/jbc.M111.335273.


10. R. Demir, M. Leuwer, J. de la Roche, K. Krampfl, et al., Pharmacology, 83(5), 270-4 (2009); doi: 10.1159/000209291.


11. V. Di Marzo, Nature reviews. Drug discovery, 7(5), 438-55 (2008); doi: 10.1038/nrd2553.


12. V. Di Marzo and L. De Petrocellis, Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 367(1607), 3216-28 (2012); doi: 10.1098/rstb.2011.0382.


13. Z. Fišar, N. Singh, and J. Hroudová, Toxicology letters, 231(1), 62-71 (2014); doi: 10.1016/j.toxlet.2014.09.002.


14. B. M. Ford, S. Tai, W. E. Fantegrossi, and P. L. Prather, Trends in pharmacological sciences, 38(3), 257-276 (2017); doi: 10.1016/j.tips.2016.12.003.


15. J. M. Franklin and G. A. Carrasco, Synapse (New York, N.Y.), 67(3), 145-59 (2013); doi: 10.1002/syn.21626.


16. T. F. Gamage, C. E. Farquhar, R. J. McKinnie, R. C. Kevin, et al., The Journal of pharmacology and experimental therapeutics, 368(3), 414-422 (2019); doi: 10.1124/jpet.118.254425.


17. F. Grotenhermen, Clinical pharmacokinetics, 42(4), 327-60 (2003); doi: 10.2165/00003088-200342040-00003.


18. A. C. Howlett and M. E. Abood, Advances in pharmacology (San Diego, Calif.), 80, 169-206 (2017); doi: 10.1016/bs.apha.2017.03.007.


19. D. R. Janero and A. Makriyannis, Expert opinion on emerging drugs, 14(1), 43-65 (2009); doi: 10.1517/14728210902736568.


20. S. R. Kim, Y. C. Chung, E. S. Chung, K. W. Park, et al., Molecular neurobiology, 35(3), 245-54 (2007); doi: 10.1007/s12035-007-0030-1.


21. R. B. Laprairie, A. M. Bagher, M. E. Kelly, and E. M. Denovan-Wright, British journal of pharmacology, 172(20), 4790-805 (2015); doi: 10.1111/bph.13250.


22. R. B. Laprairie, K. Vemuri, E. L. Stahl, A. Korde, et al., Molecular pharmacology, 96(5), 619-628 (2019); doi: 10.1124/mol.119.116483.


23. R. J. Leo and P. D. Regno, Primary care companion to the Journal of clinical psychiatry, 2(6), 194-204 (2000); doi: 10.4088/pcc.v02n0601.


24. D. Luethi and M. E. Liechti, Archives of toxicology, 94(4), 1085-1133 (2020); doi: 10.1007/s00204-020-02693-7.


25. K. Mackie, Life sciences, 77(14), 1667-73 (2005); doi: 10.1016/j.lfs.2005.05.011.


26. S. Mallipeddi, D. R. Janero, N. Zvonok, and A. Makriyannis, Biochemical pharmacology, 128, 1-11 (2017); doi: 10.1016/j.bcp.2016.11.014.


27. C. Manera, C. Arena, and A. Chicca, Recent patents on CNS drug discovery, 10(2), 142-156 (2016); doi: 10.2174/1574889810666160519113853.


28. I. J. McGilveray, Pain research & management, 10 Suppl A, 15a-22a (2005); doi: 10.1155/2005/242516.


29. G. Meredith, M. DeLollis, and M. U. Shad, Medical Cannabis and Cannabinoids, 3(1), 74-75 (2020); doi: 10.1159/000506635.


30. M. Metna-Laurent, M. Mondésir, A. Grel, M. Vallée, et al., Current protocols in neuroscience, 80, 9.59.1-9.59.10 (2017); doi: 10.1002/cpns.31.


31. V. Micale, V. Di Marzo, A. Sulcova, C. T. Wotjak, et al., Pharmacology & therapeutics, 138(1), 18-37 (2013); doi: 10.1016/j.pharmthera.2012.12.002.


32. N. Naderi, E. Shafieirad, D. Lakpoor, A. Rahimi, et al., Iranian journal of pharmaceutical research : IJPR, 14(Suppl), 115-20 (2015).


33. V. Nadler, R. Mechoulam, and M. Sokolovsky, Neuroscience letters, 162(1-2), 43-5 (1993); doi: 10.1016/0304-3940(93)90555-y.


34. S. R. Nahorski, British journal of pharmacology, 147 Suppl 1(Suppl 1), S38-45 (2006); doi: 10.1038/sj.bjp.0706468.


35. W. F. Pendergraft, 3rd, L. C. Herlitz, D. Thornley-Brown, M. Rosner, et al., Clinical journal of the American Society of Nephrology : CJASN, 9(11), 1996-2005 (2014); doi: 10.2215/cjn.00360114.


36. V. M. Pickel, J. Chan, C. S. Kearn, and K. Mackie, The Journal of comparative neurology, 495(3), 299-313 (2006); doi: 10.1002/cne.20881.


37. A. Porcu, M. Melis, R. Turecek, C. Ullrich, et al., Neuropharmacology, 133, 107-120 (2018); doi: 10.1016/j.neuropharm.2018.01.024.


38. D. M. H. Schatzberg A. F.; Charles DeBattista, Schatzberg's Manual of Clinical Psychopharmacology. Ninth ed. 2019.


39. A. N. Schoffelmeer, F. Hogenboom, G. Wardeh, and T. J. De Vries, Neuropharmacology, 51(4), 773-81 (2006); doi: 10.1016/j.neuropharm.2006.05.019.


40. H. Sharir and M. E. Abood, Pharmacology & therapeutics, 126(3), 301-13 (2010); doi: 10.1016/j.pharmthera.2010.02.004.


41. J. P. Silva, A. M. Araújo, P. G. de Pinho, H. Carmo, et al., Toxicological sciences : an official journal of the Society of Toxicology, 169(2), 422-435 (2019); doi: 10.1093/toxsci/kfz050.


42. P. Skolnick and R. Crystal, Journal of neural transmission (Vienna, Austria : 1996), 127(2), 279-286 (2020); doi: 10.1007/s00702-019-02132-7.


43. K. Socała, D. Nieoczym, M. Pieróg, and P. Wlaź, Journal of neural transmission (Vienna, Austria : 1996), 122(9), 1239-47 (2015); doi: 10.1007/s00702-015-1391-7.


44. M. Tham, O. Yilmaz, M. Alaverdashvili, M. E. M. Kelly, et al., British journal of pharmacology, 176(10), 1455-1469 (2019); doi: 10.1111/bph.14440.


45. K. Tomiyama and M. Funada, Toxicology letters, 207(1), 12-7 (2011); doi: 10.1016/j.toxlet.2011.08.021.


46. K. Tomiyama and M. Funada, Toxicology and applied pharmacology, 274(1), 17-23 (2014); doi: 10.1016/j.taap.2013.10.028.


47. M. Vallée, S. Vitiello, L. Bellocchio, E. Hébert-Chatelain, et al., Science (New York, N.Y.), 343(6166), 94-8 (2014); doi: 10.1126/science.1243985.


48. C. H. Vinkers, J. K. Tijdink, J. J. Luykx, and R. Vis, Nederlands tijdschrift voor geneeskunde, 155(35), A4900 (2012).


49. X. F. Wang, E. Galaj, G. H. Bi, C. Zhang, et al., British journal of pharmacology, 177(8), 1865-1880 (2020); doi: 10.1111/bph.14958.


50. M. Welliver, Gastroenterology Nursing, 39(2), 137-139 (2016); doi: 10.1097/SGA.0000000000000236.


51. J. L. Wiley, T. W. Lefever, J. A. Marusich, M. Grabenauer, et al., Neuropharmacology, 110(Pt A), 143-153 (2016); doi: 10.1016/j.neuropharm.2016.07.016.


52. M. P. Wilson, D. Pepper, G. W. Currier, G. H. Holloman, Jr., et al., The western journal of emergency medicine, 13(1), 26-34 (2012); doi: 10.5811/westjem.2011.9.6866.


53. S. Zou and U. Kumar, International journal of molecular sciences, 19(3) (2018); doi: 10.3390/ijms19030833.